Agilent Technologies Inc. has launched Agilent Advanced Therapeutics, a unified CDMO solution integrating the company’s capabilities across the U.S. and Canada.
Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to provide a full suite of scalable and customizable manufacturing services.
Agilent Advanced Therapeutics’ CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development. The integrated platform aims to provide customers with streamlined access to development and manufacturing service from discovery and process development through clinical- and commercial-scale manufacturing.
“The Agilent Advanced Therapeutics solution strengthens our ability to support our customers and reinforces our long-term commitment to growth, investment, and leadership in this space,” said Agilent President and CEO, Padraig McDonnell. “For our customers, this means a more integrated experience, deeper technical partnership and a trusted team that understands what it takes to bring life-changing therapies to patients.”
